Business Context and Reporting Period
Company: Oric Pharmaceuticals, Inc. (ORIC)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2026
Business Overview: Oric is a clinical-stage biopharmaceutical company focused on overcoming resistance in cancer. The company has no approved products and generates no revenue. Its primary operations involve the development of two lead clinical programs: rinzimetostat (PRC2 inhibitor for prostate cancer) and enozertinib (EGFR inhibitor for non-small cell lung cancer). In August 2025, the company executed a strategic pipeline prioritization, eliminating its discovery research group and reducing its workforce by approximately 20% to focus resources on these two lead candidates.
Key Financial Metrics
| Metric (in thousands, except per share) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(35,767) | $(30,021) |
| Net Loss Per Share (Basic & Diluted) | $(0.34) | $(0.42) |
| Research & Development Expenses | $31,437 | $24,640 |
| General & Administrative Expenses | $8,182 | $8,078 |
| Total Operating Expenses | $39,619 | $32,718 |
| Cash, Cash Equivalents & Investments | $419,711 | $392,250 |
| Accumulated Deficit | $(728,009) | $(592,795) |
| Net Cash Used in Operating Activities | $(32,438) | $(32,533) |
| Net Cash Provided by Financing Activities | $61,140 | $11 |
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss increased by $5.7 million (19%) compared to Q1 2025, driven primarily by a $6.8 million increase in R&D expenses.
- R&D Spend Shift: External R&D costs for rinzimetostat rose significantly by $7.3 million to $12.1 million, reflecting advancement into dose optimization and preparation for Phase 3. Conversely, preclinical and discontinued costs decreased by $0.9 million due to the August 2025 workforce reduction.
- Financing Activity: The company raised approximately $59.9 million in net proceeds during Q1 2026 through At-The-Market (ATM) offerings, selling 4.7 million shares. There were no ATM proceeds in Q1 2025.
- Liquidity Position: Total cash, cash equivalents, and investments increased to $419.7 million from $392.3 million at the end of Q1 2025, bolstered by the recent financing.
Guidance, Outlook, and Risks
- Clinical Outlook:
- Rinzimetostat: The company selected a recommended Phase 3 dose (400 mg QD) in combination with darolutamide for metastatic castration-resistant prostate cancer (mCRPC). The first global Phase 3 trial (Himalayas-1) is expected to initiate soon.
- Enozertinib: The company selected 80 mg QD as the monotherapy dose for Phase 3 development in NSCLC. Data readouts for first-line NSCLC patients are expected in the second half of 2026.
- Liquidity Runway: Management believes existing cash, cash equivalents, and investments are sufficient to fund operations into the second half of 2028.
- Regulatory Status Change: As of December 31, 2025, the company ceased to be an "emerging growth company" and a "smaller reporting company," resulting in increased compliance costs and reporting requirements.
- Key Risks:
- Capital Needs: The company has no revenue and expects to incur significant losses for the foreseeable future. Additional financing will be required to complete development and commercialization.
- Third-Party Dependence: Reliance on third-party manufacturers for API and drug product, including suppliers in China, exposes the company to supply chain disruptions and geopolitical risks (tariffs, trade restrictions).
- Intellectual Property: Risks related to the enforcement of patents and potential infringement claims by third parties.
- Legal Proceedings: The company's Chief Business Officer was found liable for insider trading in a matter unrelated to Oric (involving a prior employer) and is currently appealing the decision.
Investor Verification Checklist
- Runway Validation: Verify the accuracy of the "second half of 2028" liquidity projection given the increased burn rate from advancing Phase 3 trials.
- Supply Chain Resilience: Assess the specific exposure to Chinese suppliers for Active Pharmaceutical Ingredients (API) and the impact of recent U.S. tariffs and the BIOSECURE Act.
- Phase 3 Trial Initiation: Monitor the timeline for the initiation of the Himalayas-1 Phase 3 trial for rinzimetostat.
- Capital Markets Access: Evaluate the sustainability of the ATM offering program as a primary funding source and potential dilution impacts.
- Legal Exposure: Review the status of the appeal regarding the Chief Business Officer's insider trading conviction and any potential reputational or governance implications.